Caricamento...
Guselkumab for the Treatment of Psoriasis: A Review of Phase III Trials
INTRODUCTION: Interleukin (IL)-23 inhibitors are a new class of biologics currently undergoing clinical trials for the treatment of moderate-to-severe psoriasis. Phase III studies of guselkumab, an IL-23 receptor monoclonal antibody, are currently underway. METHODS: We summarize the available phase...
Salvato in:
| Pubblicato in: | Dermatol Ther (Heidelb) |
|---|---|
| Autori principali: | , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Springer Healthcare
2017
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5574739/ https://ncbi.nlm.nih.gov/pubmed/28639011 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13555-017-0187-0 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|